Veracyte(VCYT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth, driven by a 21% growth in the core testing business [5][25] - Full year total revenue reached $517 million, achieving 16% growth, with nearly 170,000 patients provided clinically actionable information [6][28] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [7][28] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, while Afirma grew 12%, contributing to a total testing volume growth of 16% [5][25] - Testing revenue during Q4 was $135.8 million, an increase of 21% year-over-year, with Decipher and Afirma revenue growth of 27% and 16%, respectively [25][26] - Approximately 18,250 Afirma tests were delivered in Q4, representing 12% volume growth, while Decipher tests reached approximately 27,200, marking 15 consecutive quarters of over 20% year-over-year volume growth [9][11] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The market penetration for Decipher is approximately 33%, indicating significant room for growth as two-thirds of patients are still not utilizing the test [12][52] - The bladder cancer segment is currently a small portion of Decipher's total volume, but there is potential for increased use as clinical evidence develops [80] Company Strategy and Development Direction - The company plans to launch two major products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [8][24] - The company aims to sustain double-digit growth through its portfolio of tests in prostate, thyroid, bladder, and breast cancer [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit revenue growth, supported by a strong pipeline and operational efficiencies [7][24] - The company is focused on building clinical evidence and expanding its market presence, particularly in advanced disease settings [15][19] - Management highlighted the importance of investing in growth drivers while maintaining profitability [28][46] Other Important Information - The company completed the transition of Afirma to a more scalable, lower-cost v2 transcriptome platform, improving operational efficiency [7][10] - The company has a strong cash position, ending the quarter with $412.9 million in cash and cash equivalents, providing flexibility for future investments [25][28] Q&A Session Summary Question: Guidance and Assumptions for 2026 - Management reiterated strong conviction in the 2026 guidance, with factors influencing the high and low ends of the range discussed [32][34] Question: Market Expansion for Prosigna - The potential market for Prosigna is significant, with 225,000 patients annually expected to be addressed by the indication [40] Question: Competitive Dynamics in Decipher Market - Management noted no significant changes in competitive dynamics, with Decipher continuing to show strong growth supported by clinical evidence [52][54] Question: Capital Allocation Strategy - The company maintains a deliberate approach to capital allocation, focusing on organic growth and infrastructure development [69][70]